PubRank

Samuel S Lee

Author PubWeight™ 83.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010 3.57
2 Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2010 2.81
3 Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010 2.32
4 Refractory ascites: pathogenesis, definition and therapy of a severe complication in patients with cirrhosis. Liver Int 2010 2.32
5 Recent variceal bleeding: Doppler US hepatic vein waveform in assessment of severity of portal hypertension and vasoactive drug response. Radiology 2006 1.95
6 Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol 2011 1.79
7 A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006 1.67
8 Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Gastroenterology 2013 1.63
9 Hepatitis C: a review for primary care physicians. CMAJ 2006 1.60
10 Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2010 1.60
11 Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology 2002 1.50
12 The diversity of O-linked glycans expressed during Drosophila melanogaster development reflects stage- and tissue-specific requirements for cell signaling. J Biol Chem 2008 1.47
13 Cardiac hepatopathy: clinical, hemodynamic, and histologic characteristics and correlations. Hepatology 2003 1.42
14 Journals' impact and pecking order: tyranny and tyrannosaurs. Liver Int 2012 1.39
15 Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol 2010 1.38
16 Brain-specific rescue of Clock reveals system-driven transcriptional rhythms in peripheral tissue. PLoS Genet 2012 1.27
17 The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. Am J Gastroenterol 2007 1.25
18 Cirrhotic cardiomyopathy. Semin Liver Dis 2008 1.21
19 Therapy insight: Cirrhotic cardiomyopathy. Nat Clin Pract Gastroenterol Hepatol 2006 1.19
20 Hemodynamic alterations in cirrhosis and portal hypertension. Korean J Hepatol 2010 1.18
21 Hepatocellular carcinoma incidence trends in Canada: analysis by birth cohort and period of diagnosis. Liver Int 2008 1.13
22 Damping index of Doppler hepatic vein waveform to assess the severity of portal hypertension and response to propranolol in liver cirrhosis: a prospective nonrandomized study. Liver Int 2007 1.11
23 Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol 2005 1.10
24 miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci U S A 2013 1.06
25 Cardiac and vascular changes in cirrhosis: pathogenic mechanisms. World J Gastroenterol 2006 1.06
26 Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension. J Hepatol 2011 1.05
27 Cirrhotic cardiomyopathy. Orphanet J Rare Dis 2007 1.03
28 Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol 2007 1.02
29 Mitogen-induced upregulation of hepatitis C virus expression in human lymphoid cells. J Gen Virol 2005 1.02
30 How to optimize HCV therapy in genotype 1 patients: management of side-effects. Liver Int 2013 1.01
31 Prediction of cardiac complications after liver transplantation. Transplantation 2009 1.00
32 Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am J Gastroenterol 2005 0.99
33 Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005 0.98
34 Amiodarone hepatotoxicity. Curr Vasc Pharmacol 2008 0.98
35 The role of selectins and integrins in adenovirus vector-induced neutrophil recruitment to the liver. Eur J Immunol 2002 0.97
36 Management of hepatitis C virus genotype 4. J Gastroenterol Hepatol 2004 0.97
37 Evaluation of VCH-759 monotherapy in hepatitis C infection. J Hepatol 2009 0.97
38 Cirrhotic cardiomyopathy. Gastroenterol Clin Biol 2002 0.95
39 Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) 2002 0.93
40 Emergency management of bleeding esophageal varices: drugs, bands or sleep? Can J Gastroenterol 2006 0.92
41 Hyperdynamic circulation in portal-hypertensive rats is dependent on central c-fos gene expression. Hepatology 2002 0.90
42 Portal vein thrombosis: should anticoagulation be used? Curr Gastroenterol Rep 2013 0.89
43 Profound suppression of chronic hepatitis C following superinfection with hepatitis B virus. Liver Int 2007 0.88
44 Cirrhotic cardiomyopathy. Ann Hepatol 2006 0.88
45 Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity. Cancer Discov 2013 0.87
46 Nuclear factor-kappaB inhibition improves myocardial contractility in rats with cirrhotic cardiomyopathy. Liver Int 2008 0.85
47 Cardiac dysfunction in spontaneous bacterial peritonitis: a manifestation of cirrhotic cardiomyopathy? Hepatology 2003 0.85
48 Cheating in scientific publishing: the scourge must stop! Liver Int 2008 0.85
49 Concurrence of primary biliary cirrhosis and antiphospholipid antibody syndrome. Am J Gastroenterol 2004 0.84
50 B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol 2013 0.84
51 Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial. Clin Infect Dis 2013 0.84
52 Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy. Can J Gastroenterol 2013 0.83
53 Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis. Inflamm Bowel Dis 2007 0.83
54 Endocannabinoids and liver disease. V. endocannabinoids as mediators of vascular and cardiac abnormalities in cirrhosis. Am J Physiol Gastrointest Liver Physiol 2008 0.82
55 What happens to cirrhotic cardiomyopathy after liver transplantation? Hepatology 2005 0.81
56 Altered mesenteric venous capacitance and volume pooling in cirrhotic rats are mediated by nitric oxide. Am J Physiol Gastrointest Liver Physiol 2008 0.80
57 Role of cardiac myofilament proteins titin and collagen in the pathogenesis of diastolic dysfunction in cirrhotic rats. J Hepatol 2011 0.79
58 Pay now or pay (more) later: tracking the costs of hepatitis C infection. Can J Gastroenterol 2010 0.79
59 Viral suppression and cirrhosis regression with tenofovir disoproxil fumarate in Asians with chronic hepatitis B. Dig Dis Sci 2014 0.79
60 Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J Hepatol 2010 0.78
61 Acute-on-chronic liver failure: the heart and systemic hemodynamics. Curr Opin Crit Care 2011 0.78
62 Hepatic nodular regenerative hyperplasia in a patient with advanced carcinoid tumor. Eur J Gastroenterol Hepatol 2009 0.77
63 Role of ICAM-1 in chronic hepatic allograft rejection in the rat. Am J Physiol Gastrointest Liver Physiol 2002 0.77
64 The spleen is a player in portal hypertension. Exp Physiol 2012 0.77
65 Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis. Expert Opin Pharmacother 2013 0.76
66 Acute coinfection with hepatitis B and hepatitis C viruses. Can J Gastroenterol 2005 0.76
67 Vasopressin antagonists and dilutional hyponatremia. Can J Gastroenterol 2004 0.76
68 Hemodynamics in the immediate post-transplantation period in alcoholic and viral cirrhosis. World J Gastroenterol 2010 0.76
69 Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change. Can J Gastroenterol 2011 0.76
70 High rates of viral suppression after long-term entecavir treatment of Asian patients with hepatitis B e antigen-positive chronic hepatitis B. Clin Gastroenterol Hepatol 2012 0.75
71 Impact of pharmaceutical industry versus university sponsorship on survey response: a randomized trial among Canadian hepatitis C care providers. Can J Gastroenterol 2007 0.75
72 Predicting cardiovascular complications after liver transplantation: 007 to the rescue? Liver Transpl 2011 0.75
73 Acute management and secondary prophylaxis of esophageal variceal bleeding: a western Canadian survey. Can J Gastroenterol 2006 0.75
74 Liver transplantation for alcoholic liver disease: a devilish dilemma. Can J Gastroenterol 2013 0.75
75 Hepatitis C, insulin resistance and fatty liver: bad things come in threes. Can J Gastroenterol 2012 0.75
76 Chronic hepatitis C in Western Canada: a survey of practice patterns among gastroenterologists in Alberta and British Columbia. Can J Gastroenterol Hepatol 2013 0.75
77 PPARα activation in portal hypertension. Hepatology 2012 0.75
78 Chronic hepatitis B--who should be treated? MedGenMed 2006 0.75
79 Correction: Hepatitis B Virus (HBV) Variants in Untreated and Tenofovir Treated Chronic Hepatitis B (CHB) Patients During Pregnancy and Post-Partum Follow-up. PLoS One 2015 0.75
80 Hepatitis C virus infection in Canada's First Nations people: a growing problem. Can J Gastroenterol 2013 0.75
81 Authorship: pride and proliferation. Liver Int 2009 0.75
82 Pleasing and displeasing things. Liver Int 2010 0.75
83 Editor's report: reflections on the first year. Liver Int 2008 0.75
84 Identifying HCV genotype 1 patients at risk of relapse. Eur J Gastroenterol Hepatol 2010 0.75
85 Is pre-treatment liver biopsy necessary for all hepatitis C genotypes? Ann Hepatol 2011 0.75
86 Protective effects of erythropoietin on cirrhotic cardiomyopathy in rats. Dig Liver Dis 2012 0.75
87 How to write a paper: an editor's tips. Liver Int 2008 0.75
88 Change in lipid profile and impairment of endothelium-dependent relaxation of blood vessels in rats after bile duct ligation. Life Sci 2003 0.75
89 'Foie cardiaque': a new name for an old syndrome? Liver Int 2008 0.75
90 Gens Una Sumus--still. Liver Int 2013 0.75
91 Treatment of HBeAg-positive patients with nucleos/tide analogues. Liver Int 2009 0.75
92 Health and socioeconomic status differences among antibody hepatitis C positive and negative transfusion recipients, 1986-1990. Can J Public Health 2003 0.75
93 The power of one and saving private Braillon. Liver Int 2012 0.75